Trial Profile

A Randomized, Double-blind, Two-arm Study Comparing the Efficacy and Safety of Trazodone Contramid OAD and Placebo in the Treatment of Unipolar Major Depressive Disorder.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 24 Jan 2011

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Trazodone (Primary)
Indications Depression; Depressive disorders; Major depressive disorder
Focus Registrational; Therapeutic Use
Sponsors Altus Formulation Inc

Most Recent Events

20 Jan 2011 Labopharm received Health Canada Approval for Oleptro for the treatment of MDD based on results of this study, according to a Labopharm media release
05 Feb 2010 The US FDA has approved Oleptro (trazodone) for the treatment of major depressive disorder.
05 Aug 2009 An NDA has been submitted to Health Canada based on positive data from this trial and five pivotal pharmacokinetic studies.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com